• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 9, 2024
Discovery & Translation

AACR brings new modalities, new targets to glioblastoma

BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
Read More
BioCentury | Apr 3, 2024
Emerging Company Profile

Calluna: targeting upstream innate immune amplifiers

The Oslo-based biotech is developing a S100A4 inhibitor that it believes could be first in class in fibrotic, immunology settings
Read More
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera's mAbs target S100 proteins implicated in driving cancer metastases
Read More
BioCentury | Aug 29, 2017
Distillery Therapeutics

Cancer

Read More
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Various

Read More
Items per page:
1 - 5 of 5